Palvella Therapeutics completed a reverse merger with Pieris Pharmaceutical of Boston to become a public traded company, with ...

After losing a major partnership last year, the Boston biotech Pieris Pharmaceutical has been searching for a path forward.

status of deep veins before deciding about newer modality of laser treatment. Varicose veins could be due to simple valve ...

目前已经明确几乎所有BAVM的发生均与基因突变有关，因此 对BAVM患者及亲属进行基因筛查的必要性是目前需要迫切关注的问题 。研究数据表明，大约90%的散发BAVM病例的病因为KRAS或BRAF体细胞激活突变 [7] 。

1 Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States 2 Department of Medicine and Cardiovascular Institute, University of Pennsylvania ...

The global arteriovenous fistula treatment market is on the verge of significant expansion, with a promising trajectory poised to reshape the treatment landscape. According to recent market analysis, ...

The global neurovascular device market is projected to grow from USD 3.0 billion in 2024 to USD 3.9 billion by 2034, ...

Palvella Therapeutics to debut on Nasdaq under the ticker symbol “PVLA” as a publicly traded rare disease biopharmaceutical company ...

There's been a rise in young and middle-aged U.S. adults experiencing catastrophic brain bleeds. A neurologist explains the ...

WAYNE, PA — Palvella Therapeutics, Inc. has completed its merger with Pieris Pharmaceuticals, Inc., forming a unified company ...

Arteriovenous malformation (AVM) is a blood vessel abnormality that, when ruptured, causes a hemorrhagic stroke. Sometimes, AVMs can also cause neurologic deficits by “stealing” blood flow from the ...